Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. The underlying cause of adenoid cystic carcinoma (ACC) is not yet known, but it appears to develop from non-inherited, genetic changes that occur during a person’s lifetime. According to the Oral Cancer Foundation, Adenoid cystic carcinoma (ACC) is a form of malignant neoplasm that arises within secretory glands, most commonly the major and minor salivary glands of the head and neck. Other sites of origin include the trachea, lacrimal gland, breast, skin, and vulva.
The exact underlying cause of adenoid cystic carcinoma is unknown. Researchers speculate that genetic and immunologic abnormalities, environmental factors (exposure to ultraviolet rays, certain chemicals, and ionizing radiation), diet, stress, and other factors may play contributing roles in causing specific types of cancer.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market
The Adenoid Cystic Carcinoma (ACC) market report also covers emerging drugs, current treatment practices, Adenoid Cystic Carcinoma (ACC) market share of the individual therapies, current and forecasted Adenoid Cystic Carcinoma (ACC) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Adenoid Cystic Carcinoma (ACC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Adenoid Cystic Carcinoma (ACC) Market Key Facts
As per the National Organization for Rare Disorders (NORD), 58% of ACC patients have tumors in the oral cavity salivary glands, and pharynx followed by 17% in the respiratory system, 12% in the breast, and the remaining 13% of tumors occur in other areas of the body, such as on the skin, lacrimal glands, prostate, etc.
According to the Adenoid Cystic Carcinoma Organization, each year, there are approximately 566,000 people diagnosed with cancer in the US, and only about 1224 of them are diagnosed with ACC. Approximately 918 people die from ACC each year.
A review by Berardinis et al. titled “Adenoid Cystic Carcinoma of Head and Neck” stated that the ACC has a global incidence of 3–4.5 cases per million per year.
Key Benefits of Adenoid Cystic Carcinoma (ACC) Market Report
-
Adenoid Cystic Carcinoma (ACC) market report provides an in-depth analysis of Adenoid Cystic Carcinoma (ACC) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Adenoid Cystic Carcinoma (ACC) market report will help in developing business strategies by understanding the Adenoid Cystic Carcinoma (ACC) Market trends & developments, key players and future market competition that will shape and drive the Adenoid Cystic Carcinoma (ACC) market in the upcoming years.
-
The Adenoid Cystic Carcinoma (ACC) market report covers Adenoid Cystic Carcinoma (ACC) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Adenoid Cystic Carcinoma (ACC) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Adenoid Cystic Carcinoma (ACC) Market
In the current market scenario, the standard treatment for Adenoid Cystic Carcinoma (ACC) includes Surgery followed by radiation therapy and medical therapy.
The Adenoid Cystic Carcinoma (ACC) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Adenoid Cystic Carcinoma (ACC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Adenoid Cystic Carcinoma (ACC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Adenoid Cystic Carcinoma (ACC) Epidemiology
The Adenoid Cystic Carcinoma (ACC) epidemiology section covers insights about historical and current Adenoid Cystic Carcinoma (ACC) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Adenoid Cystic Carcinoma (ACC) Drugs Uptake and Key Market Players
The Adenoid Cystic Carcinoma (ACC) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adenoid Cystic Carcinoma (ACC) market or expected to get launched in the market during the study period. The analysis covers Adenoid Cystic Carcinoma (ACC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Adenoid Cystic Carcinoma (ACC) market are anticipated to change in the upcoming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period. Companies across the globe are diligently working toward the development of new treatment therapies for ACC.
Some of the key companies in the Adenoid Cystic Carcinoma (ACC) market includes:
Cellestia Biotech AG
Ayala
CureVac
And others.
Adenoid Cystic Carcinoma (ACC) Therapies covered:
CB-103
AL101
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Adenoid Cystic Carcinoma (ACC) Competitive Intelligence Analysis
4. Adenoid Cystic Carcinoma (ACC) Market Overview at a Glance
5. Adenoid Cystic Carcinoma (ACC) Disease Background and Overview
6. Adenoid Cystic Carcinoma (ACC) Patient Journey
7. Adenoid Cystic Carcinoma (ACC) Epidemiology and Patient Population
8. Adenoid Cystic Carcinoma (ACC) Treatment Algorithm, Current Treatment, and Medical Practices
9. Adenoid Cystic Carcinoma (ACC) Unmet Needs
10. Key Endpoints of Adenoid Cystic Carcinoma (ACC) Treatment
11. Adenoid Cystic Carcinoma (ACC) Marketed Products
12. Adenoid Cystic Carcinoma (ACC) Emerging Therapies
13. Adenoid Cystic Carcinoma (ACC) Seven Major Market Analysis
14. Attribute Analysis
15. Adenoid Cystic Carcinoma (ACC) Market Outlook (7 major markets)
16. Adenoid Cystic Carcinoma (ACC) Access and Reimbursement Overview
17. KOL Views on the Adenoid Cystic Carcinoma (ACC) Market.
18. Adenoid Cystic Carcinoma (ACC) Market Drivers
19. Adenoid Cystic Carcinoma (ACC) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Adenoid Cystic Carcinoma (ACC) – Epidemiology Forecast to 2030
DelveInsight’s Adenoid Cystic Carcinoma (ACC) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Adenoid Cystic Carcinoma (ACC) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/